Table 1.

Demographic data, clinical characteristics and laboratory parameters of study patients [n=32]

Characteristic	Patients
Age median in years (IQR)	40 ( 31.5-50.5)
Male/female	23/9
Comorbidities	No. of patients (%)
Chronic kidney disease	6 (18.5)
Diabetes mellitus	3 (9.38)
Hypertension	4 (12.50)
Coronary artery disease	3 (9.38)
HIV	4 (12.50)
Chronic liver disease	3 (9.38)
Others	11 (34.37)
Status of ATT
ATT completed	8 (25)
On ATT treatment	19 (59.37)
ATT started after the COVID diagnosis	5 (15.62)
Site of TB
Pulmonary (previous treatment)	7 (21.87)
Pulmonary (current)	8 (25)
Tubercular meningitis	9 (28.12)
Abdominal TB	3 (9.3)
TB involving more than one site	5 (15.62)
Presenting complaints [n=32]	No. (%)
Shortness of breath	18 (56.25)
Cough	15 (46.88)
Fever	12 (37.50)
Altered sensorium	12 (37.50)
Seizure	4 (12.50)
Others	13 (40.63)
Initial respiratory support	No. (%)
Room air	8 (25)
Oxygen by face mask	8 (25)
Oxygen by HFNC	7 (21.8)
Invasive ventilation	9 (28.1)
Highest respiratory support
Oxygen by face mask	8 (25)
Oxygen by HFNC	5 (15.6)
Invasive ventilation	19 (59.3)
Chest X-ray findings	No. (%)
Active TB	12 (37.50)
Post TB sequelae	10 (31.2)
Features of COVID	23 (71.8)
Severity indices and inflammatory markers	Median (IQR)
Initial SOFA (n=32)	4 (3-7)
IL6 (pg/mL) (n=26)	53.5 (19-105)
Ferritin (µg/L ) (n=24)	405 (216-940)
CRP (mg/dL) (n=22)	9.3 (4.05-20.7)
Procalcitonin (ng/mL) (n=16)	2.8 9 (0.4-6.6)
SOFA at 48 h (n=29)	5 (4-6)
Duration of hospital stay (days) (n=32)	11.5 (7-19.5)

Data are presented as median [IQR] or number (percentages). IQR=Interquartile range, HIV=Human immunodeficiency virus, ATT=Anti tubercular treatment, TB=Tuberculosis, HFNC=High frequency nasal cannula, SOFA=Sequential Organ Failure Assessment, IL-6=Interleukin- 6, CRP=C-reactive protein